TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma
Started June 22, 2020
320
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Started April 1, 2019
334
TG-1601 is a Novel BET Inhibitor with Strong Binding Affinity and Long-lasting Effect in Pre-clinical Models
Started April 18, 2018
418
Preclinical Characterization of a Fully Human lgG1 Anti PD-L1 mab CK-301
Started April 4, 2017
397
Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor.
Started April 16, 2016
481
IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas.
Started April 18, 2015
446
The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.
Started April 9, 2014
379
The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro.
Started April 9, 2014
273
The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro.
Started September 9, 2013
308
Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth.
Started April 4, 2012
516